Teva amends Rule 144 listing 447,778 ordinary shares

Teva Pharmaceutical Industries Limited filed an amendment to a Rule 144 notice that lists proposed disposition of 447,778 ordinary shares through Citigroup Global Markets.

Accepted by SEC EDGAR 02/18/2026 - 06:28 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited filed an amendment to a Rule 144 notice that lists proposed disposition of 447,778 ordinary shares through Citigroup Global Markets. The amendment also lists 161,656 restricted share units and 620,110 performance share units, each dated 02/15/2023, with an entry date of 02/17/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144/A list as the security and quantity?

The filing lists ordinary shares and specifies 447,778 shares slated in the amendment. It identifies Citigroup Global Markets as the broker and includes related equity awards dated 02/15/2023.

Does the 144/A show equity awards tied to the TEVA shares?

Yes. The amendment records 161,656 restricted share units and 620,110 performance share units, both dated 02/15/2023. Those award counts are included in the filing's security lines.

Which broker-dealer is named in the TEVA 144/A amendment?

The filing names Citigroup Global Markets at 390 Greenwich Street, New York, NY, as the broker-dealer associated with the listed ordinary shares. That broker appears alongside the 447,778 shares line.

What dates are shown in the TEVA 144/A amendment?

The document shows award grant dates of 02/15/2023 for the RSUs and PSUs and an entry or filing date of 02/17/2026. Those dates appear in the security and award lines.

Does the amendment state how proceeds will be used or received?

The excerpt does not state the use of proceeds or who will receive sale proceeds. The amendment lists security quantities, award types, broker name, and dates but contains no proceeds allocation language.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001673277
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001973379-26-000038
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Francis Richard D
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	PRESIDENT AND CEO

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	447778	15324798.00	1149812898	02/17/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	02/15/2023	RESTRICTED SHARE UNIT AWARD	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			161656	02/17/2026	COMPENSATION
ORDINARY SHARES	02/15/2023	PERFORMANCE SHARE UNIT AWARD	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			620110	02/17/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks	SECTION 3 E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES SHARES WERE SOLD PURSUANT TO A 10B51 PLAN ESTABLISHED IN NOVEMBER 2025. SHARES THAT WERE SOLD IN SOME CASES WERE TO COVER REQUIRED OBLIGATIONS. SECTION 3 D AGGREGATE FMV WAS PROPERLY UPDATED
Date of Notice	02/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)